Andera Partners to sell its Life Sciences’ portfolio company ReViral to Pfizer
Summary
Andera co-led the Series A of $21 million in 2015 and re-invested in the subsequent financing rounds alongside a group of international blue chip investors. ReViral has a portfolio of promising therapeutic candidates, including sisunatovir, an orally administered inhibitor designed to block fusion of the RSV virus to the host cell. We are extremely proud that the work accomplished to date has been recognized by a world-class leader such as Pfizer, and the development of these important therapeutic products will continue.” “We are grateful to Andera to have funded and supported us since the early days of the company, alongside a group of leading international investors. Created over 20 years ago, Andera Partners is a major player in private company investments in France and internationally. Responsible and committed, the management company regularly forms partnerships with non-profit sector entities and takes concrete action in the fight against global warming.